[{"address1": "55 Cambridge Parkway", "address2": "Suite 901 East", "city": "Cambridge", "state": "MA", "zip": "02142", "country": "United States", "phone": "857 999 0075", "fax": "866 553 3269", "website": "https://www.kalvista.com", "industry": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE). It develops Factor XIIa, an oral inhibitor for the treatment of HAE which is in preclinical trial. In addition, the company is developing an orally disintegrating tablet formulation, including KONFIDENT-KID for pediatric use with HAE; KONFIDENT-S for adolescent and adult patients with type I or type II HAE; and KONFIDENT for a potential oral therapy for HAE attacks. The company is headquartered in Cambridge, Massachusetts.", "fullTimeEmployees": 150, "companyOfficers": [{"maxAge": 1, "name": "Mr. Benjamin L. Palleiko", "age": 57, "title": "CEO & Director", "yearBorn": 1966, "fiscalYear": 2024, "totalPay": 983070, "exercisedValue": 0, "unexercisedValue": 776524}, {"maxAge": 1, "name": "Dr. Christopher M. Yea Ph.D.", "age": 59, "title": "Chief Development Officer", "yearBorn": 1964, "fiscalYear": 2024, "totalPay": 708532, "exercisedValue": 0, "unexercisedValue": 2934521}, {"maxAge": 1, "name": "Dr. Paul K. Audhya M.B.A., M.D.", "age": 50, "title": "Chief Medical Officer", "yearBorn": 1973, "fiscalYear": 2024, "totalPay": 736815, "exercisedValue": 0, "unexercisedValue": 25589}, {"maxAge": 1, "name": "Mr. Brian  Piekos", "age": 48, "title": "Chief Financial Officer", "yearBorn": 1975, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Ryan  Baker", "title": "Head of Investor Relations", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Brian  Krex J.D.", "age": 55, "title": "General Counsel", "yearBorn": 1968, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Jarrod  Aldom", "title": "Vice President of Corporate Communications", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Rachel M. Morten", "title": "Senior Vice President of Regulatory Affairs & QA", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Michael D. Smith Pharm.D.", "age": 43, "title": "Senior Vice President of Development", "yearBorn": 1980, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Nicole  Sweeny", "age": 47, "title": "Chief Commercial Officer", "yearBorn": 1976, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 6, "boardRisk": 6, "compensationRisk": 8, "shareHolderRightsRisk": 5, "overallRisk": 6, "governanceEpochDate": 1727740800, "compensationAsOfEpochDate": 1735603200, "maxAge": 86400, "priceHint": 2, "previousClose": 11.98, "open": 12.1, "dayLow": 11.933, "dayHigh": 12.5, "regularMarketPreviousClose": 11.98, "regularMarketOpen": 12.1, "regularMarketDayLow": 11.933, "regularMarketDayHigh": 12.5, "beta": 0.889, "forwardPE": -7.8535028, "volume": 235413, "regularMarketVolume": 235413, "averageVolume": 352290, "averageVolume10days": 274110, "averageDailyVolume10Day": 274110, "bid": 12.17, "ask": 12.26, "bidSize": 100, "askSize": 100, "marketCap": 533290976, "fiftyTwoWeekLow": 7.21, "fiftyTwoWeekHigh": 16.88, "fiftyDayAverage": 11.8089, "twoHundredDayAverage": 12.4592, "currency": "USD", "enterpriseValue": 365258912, "floatShares": 26081402, "sharesOutstanding": 43215500, "sharesShort": 6508122, "sharesShortPriorMonth": 5645899, "sharesShortPreviousMonthDate": 1724976000, "dateShortInterest": 1727654400, "sharesPercentSharesOut": 0.1506, "heldPercentInsiders": 0.01442, "heldPercentInstitutions": 1.2146, "shortRatio": 12.17, "shortPercentOfFloat": 0.1734, "bookValue": 4.011, "priceToBook": 3.0740461, "lastFiscalYearEnd": 1714435200, "nextFiscalYearEnd": 1745971200, "mostRecentQuarter": 1722384000, "netIncomeToCommon": -141770000, "trailingEps": -3.57, "forwardEps": -1.57, "lastSplitFactor": "1:14", "lastSplitDate": 1479772800, "enterpriseToEbitda": -2.361, "exchange": "NGM", "quoteType": "EQUITY", "symbol": "KALV", "underlyingSymbol": "KALV", "shortName": "KalVista Pharmaceuticals, Inc.", "longName": "KalVista Pharmaceuticals, Inc.", "firstTradeDateEpochUtc": 1428586200, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "855accb6-3648-3882-a18c-cf430f76475f", "gmtOffSetMilliseconds": -14400000, "currentPrice": 12.33, "targetHighPrice": 39.0, "targetLowPrice": 20.0, "targetMeanPrice": 30.17, "targetMedianPrice": 33.5, "recommendationMean": 1.6, "recommendationKey": "buy", "numberOfAnalystOpinions": 6, "totalCash": 174272000, "totalCashPerShare": 4.033, "ebitda": -154720000, "totalDebt": 6252000, "quickRatio": 8.325, "currentRatio": 8.551, "debtToEquity": 3.618, "returnOnAssets": -0.53937, "returnOnEquity": -0.90839, "freeCashflow": -57843376, "operatingCashflow": -102721000, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-10-17"}]